AIM Kanghuai Biopharmaceutical

AIM Kanghuai Biopharmaceutical (now officially known as AIM Action Biopharmaceutical) is a specialized vaccine manufacturer based in Taizhou, China, and a wholly-owned subsidiary of the publicly traded AIM Vaccine Co., Ltd. Established in 2011, the company focuses on the development and large-scale production of viral vaccines using advanced human diploid cell culture and microcarrier fermentation technologies. Its flagship product is an inactivated hepatitis A vaccine, which received its New Drug Application (NDA) approval in 2015, positioning the company as one of the few domestic suppliers in the Chinese market. Beyond its commercial portfolio, AIM Kanghuai is advancing a clinical-stage pipeline, including a bivalent vaccine for Hand, Foot, and Mouth Disease (HFMD) targeting Enterovirus 71 and Coxsackievirus A16. The company operates within the China Medical City industrial cluster, leveraging a fully integrated value chain to support the prevention and control of major infectious diseases.